GlaxoSmithKline PLC's severe asthma treatment Nucala will need to be significantly discounted to make it cost-effective, according to a draft report on the product's value by the Institute for Clinical and Economic Review released Dec. 21.
Nucala (mepolizumab), a physician-administered biologic approved Nov. 4, is priced at a wholesale acquisition cost (WAC) of $32,500 per year of use ([A#14151104009])